Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.68 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.68 |
| ▸ | NPY2R | P49146 | 8/20 | 0.61 |
| ▸ | NPY4R | P50391 | 8/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.61 |
| ▸ | NPY1R | P25929 | 6/20 | 0.61 |
| ▸ | CALCR | P30988 | 5/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.58 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurotensin SCHEMBL30483709 | 0.87 | KDM1A (0.61) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL30957024 | 0.87 | KDM1A (0.61) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL31000874 | 0.87 | NPY2R (0.64) | HCRTR1HCRTR2NPY2RNPY4RNPY5R | |
| SCHEMBL30435444 | 0.87 | OPRD1 (0.67) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30648484 | 0.86 | CALCR (0.62) | HCRTR1HCRTR2NPY2RNPY4RNPY5R | |
| SCHEMBL30824294 | 0.86 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| Neurotensin SCHEMBL29357707 | 0.86 | NTSR1 (0.70) | HCRTR1HCRTR2NPY1RNTSR1OPRM1 | |
| Neurotensin SCHEMBL29851748 | 0.86 | NTSR1 (0.70) | HCRTR1HCRTR2NPY1RNTSR1OPRM1 | |
| SCHEMBL31000890 | 0.86 | NPY2R (0.63) | HCRTR1HCRTR2NPY2RNPY4RNPY5R | |
| SCHEMBL30607403 | 0.86 | CALCR (0.67) | HCRTR1HCRTR2NPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250326866-A1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDE OLIGONUCLEOTIDE COMPLEXES AND METHODS OF USE THEREOF | BLAZE BIOSCIENCE INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250195673-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DEPLETION OF TARGET MOLECULES | Blaze Bioscience, Inc. | 2025-06-19 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250051830-A1 | MEMBRANE-EMBEDDED NANOPORE AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-02-13 | — | — | US | disclosed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | disclosed |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-29 | — | — | US | disclosed |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-13 | — | — | US | disclosed |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-08-16 | — | — | US | disclosed |
| WO-2022125673-A1 | CELL-PENETRATING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022115715-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DEPLETION OF TARGET MOLECULES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | HCRTR1 1287/4885HCRTR2 890/4885NPY2R 501/4885 |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | TST, ABAT, AADAC | HCRTR1 3576/4885HCRTR2 4204/4885NPY2R 3978/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | HCRTR1 744/4885HCRTR2 648/4885NPY2R 111/4885 |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | HCRTR1 1287/4885HCRTR2 890/4885NPY2R 501/4885 |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | CXCL12, ATP6V1B1, VIP | HCRTR1 2959/4885HCRTR2 2595/4885NPY2R 674/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | HCRTR1 112/4885HCRTR2 127/4885NPY2R 150/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | HCRTR1 2440/4885HCRTR2 3295/4885NPY2R 1754/4885 |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | DNPEP, NPEPPS, PAM | HCRTR1 1287/4885HCRTR2 890/4885NPY2R 501/4885 |
| US-20250326866-A1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDE OLIGONUCLEOTIDE COMPLEXES AND METHODS OF USE THEREOF | TFRC, TEK, FOLR1 | HCRTR1 1622/4885HCRTR2 1751/4885NPY2R 529/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | HCRTR1 968/4885HCRTR2 2037/4885NPY2R 791/4885 |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | HCRTR1 3576/4885HCRTR2 4204/4885NPY2R 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.